These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 17284508)

  • 1. Moxifloxacin and torsade de pointes.
    Dale KM; Lertsburapa K; Kluger J; White CM
    Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxifloxacin-induced torsades de pointes.
    Sherazi S; DiSalle M; Daubert JP; Shah AH
    Cardiol J; 2008; 15(1):71-3. PubMed ID: 18651388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long QTc interval and torsade de pointes caused by fluconazole.
    Pham CP; de Feiter PW; van der Kuy PH; van Mook WN
    Ann Pharmacother; 2006; 40(7-8):1456-61. PubMed ID: 16849620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arrhythmias associated with fluoroquinolone therapy.
    Falagas ME; Rafailidis PI; Rosmarakis ES
    Int J Antimicrob Agents; 2007 Apr; 29(4):374-9. PubMed ID: 17241772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
    Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
    Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event.
    Altin T; Ozcan O; Turhan S; Ongun Ozdemir A; Akyurek O; Karaoguz R; Guldal M
    Can J Cardiol; 2007 Sep; 23(11):907-8. PubMed ID: 17876386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol.
    Tisdale JE; Kovacs R; Mi D; McCabe GP; Cariera BL; Sharma N; Rosman H
    Pharmacotherapy; 2007 Feb; 27(2):175-82. PubMed ID: 17253907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine.
    Vieweg WV; Schneider RK; Wood MA
    Acta Psychiatr Scand; 2005 Oct; 112(4):318-22; author reply 322. PubMed ID: 16156840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azithromycin-induced torsade de pointes.
    Huang BH; Wu CH; Hsia CP; Yin Chen C
    Pacing Clin Electrophysiol; 2007 Dec; 30(12):1579-82. PubMed ID: 18070319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QT interval prolongation, torsade de pointes and renal disease.
    Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
    Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methadone-induced torsade de pointes in a patient with normal baseline QT interval.
    Almehmi A; Malas AM; Yousufuddin M; Rosencrance JG
    W V Med J; 2004; 100(4):147-8. PubMed ID: 15471174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxifloxacin-associated neutropenia in a cirrhotic elderly woman with lower extremity cellulitis.
    Chang CM; Lee NY; Lee HC; Lee IW; Wu CJ; Lin YS; Ko WC
    Ann Pharmacother; 2008 Apr; 42(4):580-3. PubMed ID: 18349304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amiodarone-induced torsade de pointes in a child with dilated cardiomyopathy.
    Silvetti MS; Drago F; Bevilacqua M; Ragonese P
    Ital Heart J; 2001 Mar; 2(3):231-6. PubMed ID: 11305536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Torsade de Pointes with T wave alternans in a patient receiving moderate dose of chlorpromazine: report of a case].
    Ochiai H; Kashiwagi M; Usui T; Oyama Y; Tokita Y; Ishikawa T
    Kokyu To Junkan; 1990 Aug; 38(8):819-22. PubMed ID: 2218093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Female preponderance in ibutilide-induced torsade de pointes.
    Gowda RM; Khan IA; Punukollu G; Vasavada BC; Sacchi TJ; Wilbur SL
    Int J Cardiol; 2004 Jun; 95(2-3):219-22. PubMed ID: 15193823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
    Oberg KC; Bauman JL
    Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulpiride induced torsade de pointes.
    Huang BH; Hsia CP; Chen CY
    Int J Cardiol; 2007 Jun; 118(3):e100-2. PubMed ID: 17408770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.